Valiant Laboratories Ltd(VALIANTLAB)

NSE: VALIANTLABBSE: 543998

₹ 129.25-1.97%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 702 crWebsite: www.valiantlabs.inUpdated: 24 Oct 2026

About

Valiant Laboratories is an Aarti Group pharmaceutical company with over 45 years of manufacturing history. It describes itself as one of India's leading makers of Active Pharmaceutical Ingredients, with a strong presence in Paracetamol API. Revenue was 237.47 crore in FY26. Through its wholly owned subsidiary Valiant Advanced Sciences, it is also moving into specialty chemicals.^[1][2]

Business segments

The company reports a single segment, Pharmaceuticals. Revenue from within India was Rs 212.94 Cr in FY26, against Rs 132.72 Cr in FY25.^[1][3]
Revenue from outside India was Rs 4.1 Cr in FY26, against Rs 0.64 Cr in FY25.^[1][3]

Products

The company makes Paracetamol API to IP/BP/EP/USP standards, in crystal, powder and fine powder grades. Customers use it in tablets, capsules and other dosage forms (FY26).^[1]
Subsidiary VASPL makes specialty chemicals, including ketene and diketene derivatives. They are used in agrochemicals, pharmaceuticals, dyes, pigments, fragrances, food and polymers.^[1][3]

Operations and raw materials

The company runs a single manufacturing facility at Tarapur Industrial Estate, Maharashtra (FY26).^[1]
As of FY26, Aarti Group companies make both key starting materials for Paracetamol: Para-Aminophenol and Acetic Anhydride.^[1]
The company makes acetic anhydride in-house and sells surplus volumes to outside buyers (FY25).^[3]
The VASPL facility holds ISO 9001, ISO 14001, ISO 45001, Halal and Kosher certifications (FY26).^[1]
There were 84 permanent employees on 31 March 2026, against 79 on 31 March 2025.^[1]

Customers

No single customer made up 10% or more of total revenue in FY26.^[1]
VASPL has secured customer approvals for several products. More products are going through customer qualification (FY26).^[1]

Expansion

Subsidiary VASPL has set up a facility in Gujarat to make specialty chemicals such as ketene and diketene derivatives.^[3]
VASPL is classified as a material subsidiary for FY26 and FY27.^[1]
As at March 31, 2026, there were no capital contracts left to execute.^[1]

Recent developments

A rights issue completed in August 2025 raised ₹81.47 crore. Most of it went to repay the company's outstanding term borrowings in full.^[1]
A US Section 232 proclamation sets tariffs of up to 100% on patented drugs from 31 July 2026. Generics, including Paracetamol, are excluded for now; whether the tariffs extend to generics is due to be reviewed by April 2027.^[1]

Ownership

The holding entity is Dhanvallabh Ventures LLP. The ultimate holding company is Valiant Organics Limited (FY26).^[1]

Market Cap

₹702 Cr

High / Low

₹141 / 50

Stock P/E

43.8

Price / Book

2.3

Book Value

₹57

EPS

₹-0.6

No. of Shares

5.43 Cr

ROCE

0.8%

ROE

-1.2%

OPM

1.1%

Debt / Equity

0.14

Sales

₹237 Cr

Net Profit

₹-3 Cr

Promoter holding

74.9%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

No earnings calls are on record for this company, so our models read its annual report and financials end-to-end - then value the business and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
P&L bridge from reported history - worst / average / best multiple cases.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials